SCHEMBL2517599

SCHEMBL2517599

CCOC(=O)Cc1ccc(S(=O)(=O)NC)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.62
KDM4E B2RXH2 2/20 0.62
ALDH1A1 P00352 2/20 0.62
TSHR P16473 1/20 0.62
HSD17B10 Q99714 1/20 0.62
CYP4Z1 Q86W10 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
GAA P10253 3/20 0.49
MAPT P10636 2/20 0.48
NPC1 O15118 1/20 0.48
HPGD P15428 1/20 0.48
RAB9A P51151 1/20 0.48
AKT1 P31749 1/20 0.46
IRS1 P35568 1/20 0.46
GAB1 Q13480 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 1/20 0.45
LIPE Q05469 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24032613 0.85 SMN1; SMN2 (0.59) LMNAKDM4EALDH1A1TSHRHSD17B10
SCHEMBL2519148 0.84 ALDH1A1 (0.58) LMNAKDM4EALDH1A1TSHRHSD17B10
SCHEMBL18151609 0.82 TSHR (0.47) LMNAKDM4EALDH1A1TSHRHSD17B10
SCHEMBL27513611 0.82 CYP1A2 (0.62) LMNAKDM4EALDH1A1TSHRHSD17B10
SCHEMBL2665972 0.82 KMT2A (0.57) LMNAKDM4EALDH1A1TSHRHSD17B10
SCHEMBL2665963 0.82 LMNA (0.56) LMNAKDM4EALDH1A1TSHRHSD17B10
SCHEMBL18275183 0.81 POLB (0.69) LMNAKDM4EALDH1A1TSHRHSD17B10
SCHEMBL68851 0.81 CYP4Z1 (0.62) LMNAKDM4EALDH1A1TSHRHSD17B10
SCHEMBL119585 0.81 LMNA (0.54) LMNAKDM4EALDH1A1TSHRHSD17B10
SCHEMBL117475 0.80 TSHR (0.67) LMNAKDM4EALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3077372-B1 ROR GAMMA (RORY) MODULATORS LEAD PHARMA HOLDING BV (NL) 2019-02-06 EP disclosed
US-9738600-B2 ROR gamma (RORγ) modulators LEAD PHARMA CEL MODELS IP B.V. (NL) 2017-08-22 US disclosed
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2016-10-20 US disclosed
EP-3077372-A1 ROR GAMMA (RORY) MODULATORS Lead Pharma Cel Models IP B.V. (NL) 2016-10-12 EP disclosed
CN-105980353-A ROR gamma modulators 领先制药CEL模型知识产权公司 2016-09-28 CN disclosed
WO-2015082533-A1 ROR GAMMA (RORY) MODULATORS LEAD PHARMA CEL MODELS IP B.V. (NL) 2015-06-11 WO disclosed
US-8410094-B2 Amide compounds, their pharmaceutical compositions, their preparation method and their uses SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2013-04-02 US disclosed
US-20110251192-A1 AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR PREPARATION METHOD AND THEIR USES SHANGHAI TARGETDRUG CO., LTD. (CN) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251192-A1 AMIDE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR PREPARATION METHOD AND THEIR USES CCR5, CCR8, CXCR1 LMNA 4472/4885KDM4E 2036/4885ALDH1A1 2158/4885
US-20160304448-A1 ROR GAMMA (RORy) MODULATORS RORC, RORA, RORB LMNA 3089/4885KDM4E 2422/4885ALDH1A1 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.